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Table 1
Prediction Parameter OR (95%CI) P value
Maximal Medial BML Grade 7.07 (2.80-17.84) <0.0001
Maximal Medial Meniscus Grade 1.08 (0.39-2.98) 0.88
WOMAC Pain 1.09 (0.97-1.23) 0.16
Valgus anatomic axis 0.20 (0.04-0.93) 0.04
Varus anatomic axis 1.52 (0.52-4.44) 0.44
(central medial femur) the denuded area appears to show the
highest univariate relation to purported predictive risk factors of
BML grade and meniscal morphology. For clinical trial planning
screening for maximal BML grade and excluding knees with
valgus alignment will afford the greatest opportunity to detect
progression.
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Purpose: There are signiﬁcant health care costs associated with
osteoarthritis (OA) of the knee due to several factors including
both utilization of health care services and loss of productivity. We
previously reported that traditional Chinese acupuncture (TCA)
given in a tapering schedule over 26 weeks was associated
with signiﬁcantly greater improvement in pain and function when
compared to both sham acupuncture and education alone (Ann
Intern Med 2004;141:901-10). Herein, we report results of a cost
effectiveness analysis of TCA in comparison to education alone
as adjunctive treatment for knee OA.
Methods: This analysis was limited to the 190 and 189 patients
randomized to the TCA and education alone groups, respectively;
data on patients randomized to sham acupuncture were not
used in this analysis. To estimate costs, we used self-reported
data from the Health Assessment Questionnaire (HAQ) that
was completed by participants at their 26 week close-out visit
to determine health care utilization including medication use,
hospitalizations, outpatient surgeries or procedures, emergency
room visits and doctor or health care worker visits. In addition,
we included the costs of providing the interventions. To measure
effectiveness, we estimated quality adjusted life years (QALYs)
gained, based on self-reported data from the EuroQoL (EQ-5D)
completed at baseline, 8- and 26 weeks. The changes in health
utility used to estimate gains in QALYs were calculated using
generalized estimating equations to account for the multiple
observations per study subject. Missing data were assumed to
be missing at random. We used 1000 bootstrapped repetitions
to describe the distribution of the cost-effectiveness results. In a
secondary analysis, we also estimated the costs per additional
OMERACT/OARSI responder.
Results: At 26 weeks, HAQ and EQ-5D data were available
on 131 (92.3%) of 142 and 91 (84.3%) of 108 subjects who
completed the entire study period in the TCA and education
alone groups, respectively. Participants in the TCA group used
fewer medications, had fewer hospitalizations (7.6% v 8.9%),
outpatient surgeries (13.0% v 16.5%), emergency room visits
(8.4% v 11.0%) and mean number of health care worker or
doctor visits (7.1% v 7.9%), but slightly higher mean number of
nights in hospital (0.61 v 0.58) than those in the education alone
group. Over the 26-week study period, the TCA group gained
0.06 QALYs when compared to education alone group.
The median cost-effectiveness was $32,000/QALY gained. The
cost-effectiveness acceptability curve shows that 95% of 1000
repetitions were consistent with a cost-effectiveness result of
less than $50,000/QALY gained (see Figure 1). As previously
reported, 52% of the TCA group and 30% of the education alone
group could be classiﬁed as OMERACT/OARSI responders. The
cost per additional responder achieved in the TCA group was
estimated as $30,000.
Figure 1
Conclusions: These analyses, based on data from a rigorous
26-week randomized controlled trial suggest that TCA is a cost
effective modality when used as an adjunctive therapy in patients
with symptomatic OA of the knee.
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Purpose: In Osteoarthritis (OA), low-grade cartilage and joint
inﬂammation promotes dysregulated chondrocyte differentiation
and cartilage catabolism. Inﬂammatory and pro-catabolic signals
for human chondrocytes in OA are provided not only by traditional
cytokines such as IL-1, TNFalpha, and chemokines, but also by
moieties such as ﬁbronectin proteolytic fragments and the cal-
granulins S100A11 and S100A4. The calgranulins are ligands of
the patterning receptors RAGE (receptor for advanced glycation
endproducts) and CD36. S100A11, as well as TNFalpha and
CXCL8 (IL-8), induce RAGE signaling-dependent chondrocyte
hypertrophy. CD36 is a scavenger receptor whose ligands other
than calgranulins include thrombospondin and long-chain fatty
acids. PPARgamma agonists induce CD36 expression in cells
other than chondrocytes, and numerous studies have shown
PPARgamma activation to be anti-inﬂammatory. Furthermore,
the PPARgamma agonist, pioglitazone, reduces severity of ex-
perimental OA. Hence, we examined the expression and function
of CD36 in chondrocytes in vitro and in situ in experimental OA.
Methods: We employed an in vivo OA model using male
Sprague-Dawley rats that underwent joint destabilization surgery
by anterior cruciate ligament transection and partial medial
meniscectomy and forced mobilization of the joint. Since nor-
mal cultured chondrocytes did not express CD36, we transfected
CD36 to assess “gain of function” in human chondrocytes.
Results: We demonstrated that both RAGE and CD36 expres-
sion became increased by 4 weeks in vivo. RAGE expres-
